Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 32Lung Neoplasms 11Brain Neoplasms 5Meningeal Carcinomatosis 2Recurrence 1Rare Tumor 1Radiation Pneumonitis 1Non-small Cell Lung Cancer Metastatic 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 1NSCLC 1Liver Diseases 1EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor 1Digestive System Diseases 1Carcinoma 1Aumolertinib 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

Pemetrexed 14Carboplatin 13osimertinib 10aflutinib 9Drug Therapy 9Gefitinib 7Radiotherapy 6Docetaxel 6Cisplatin 6anlotinib 5Radiosurgery 5Paclitaxel 5pembrolizumab 4Vinorelbine 4Gemcitabine 4tislelizumab 3icotinib 3apatinib 3HM781-36B 3Erlotinib Hydrochloride 3toripalimab 2spartalizumab 2rezivertinib 2camrelizumab 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × NSCLC × aumolertinib × Clear all
NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated
8 enrolled 7 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡